Subject Matter of the Lobbying Activity
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Discuss Xeomin and current public payer formulary access criteria and new indications in an effort to secure coverage that reflects the current Health Canada approved indications. To discuss potential new indications and future products to assist the BC drug Formulary in preparing for future potential coverage needs.
|
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health, Hospitals
|
Problems physicians are experiencing with Special Authority forms where they are not populating for the Merz product Xeomin, but they are doing so properly for other similar products in the therapeutic space of neurology.
Footnote1
|
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
Footnote1
|
|